Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Hospital Policy / Regulatory

China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities

Fineline Cube May 7, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company Deals

Beihai Biotech Licenses Beizary to Zydus Lifesciences for US Market

Fineline Cube Feb 18, 2025

China-based Zhuhai Beihai Biotech Co., Ltd announced a licensing agreement with Zydus Lifesciences, granting the...

Company Drug

Huadong Medicine’s HDM1005 Shows Positive Results in Phase Ia/Ib Study

Fineline Cube Feb 18, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced positive results from the Phase Ia/Ib study...

Company Deals

PolyMed Biopharma Licenses HPB-143 to Photys Therapeutics for Global Development

Fineline Cube Feb 18, 2025

PolyMed Biopharma, a Hangzhou-based developer of Proteolysis Targeting Chimera (PROTAC) drugs, has entered into a...

Company Drug

Samsung Bioepis’ Ospomyv and Xbryk Gain FDA Approval for RANKL Inhibitor Biosimilars

Fineline Cube Feb 17, 2025

South Korea-based Samsung Bioepis Co., Ltd. announced that it has received marketing approval from the...

Company Drug

Kexing Biopharm’s GB05 Receives FDA Approval for Pediatric RSV Infections

Fineline Cube Feb 17, 2025

China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced that it has received clinical trial approval...

Company Drug

Sanofi’s Merilog Biosimilar Wins FDA Approval for Diabetes Treatment

Fineline Cube Feb 17, 2025

The U.S. Food and Drug Administration (FDA) has approved Sanofi-Aventis’ (EPA: SAN) Merilog, a biosimilar...

Company Deals

Yantai Dongcheng’s Lannacheng Bio Secures RMB150m to Advance [18F] Spiritide Study

Fineline Cube Feb 17, 2025

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675)’s controlling subsidiary, Yantai Lannacheng Biotechnology Co., Ltd.,...

Company Drug

GSK’s Penmenvy Meningococcal Vaccine Approved by FDA for Ages 10-25

Fineline Cube Feb 17, 2025

UK-based multinational GSK plc (LON: GSK) announced that it has received marketing approval from the...

Company Deals

3SBio and Sichuan Biokin Partner to Advance Solid Tumor Treatment in China

Fineline Cube Feb 17, 2025

China-based 3SBio Inc. (HKG: 1530) has announced a strategic partnership with fellow domestic firm Sichuan...

Company Drug

LINDIS Biotech’s Korjuny Approved by European Commission for Malignant Ascites

Fineline Cube Feb 17, 2025

Germany-based LINDIS Biotech GmbH announced that it has received market approval from the European Commission...

Company Drug

IASO Bio’s Fucaso NDA Accepted by Hong Kong DOH for Relapsed/Refractory Multiple Myeloma

Fineline Cube Feb 17, 2025

China-based IASO Bio announced that a New Drug Application (NDA) for its BCMA-targeted chimeric antigen...

Company Drug

Innovent Biologics’ IBI363 Receives FDA Fast-Track Designation for sqNSCLC

Fineline Cube Feb 17, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received another fast-track designation from...

Company Deals

Tianyi Medical Acquires Bellco’s CRRT Filter Business for EUR11.99m

Fineline Cube Feb 17, 2025

Tianyi Medical (SHE: 301097), a Ningbo-based developer of Class III medical consumables, has announced plans...

Company Drug

Konruns Pharmaceutical’s KC1036 Enters Phase II Trial for Ewing’s Sarcoma in Adolescents

Fineline Cube Feb 17, 2025

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) announced the first patient dosing in a Phase...

Company Drug

Hengrui Pharma Submits Ivarmacitinib Ointment for AD Treatment Approval

Fineline Cube Feb 17, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the submission of a marketing filing for...

Company

Deep Analysis and Strategic Insights: The Impact of Vice President Yu Bing’s Departure on BCHT Biotechnology

Fineline Cube Feb 16, 2025

In a move that has sent ripples through China’s vaccine industry, Changchun BCHT Biotechnology Co.,...

Company

Beijing Wanjie Medical Device Completes Near-Hundred Million Yuan B-Round Financing

Fineline Cube Feb 15, 2025

Beijing Wanjie Medical Device Co., Ltd. recently announced the successful completion of a B-round financing...

Company Digital

Pharmaceutical Giants Race to Integrate DeepSeek AI for Efficiency Gains

Fineline Cube Feb 15, 2025

On February 14, China’s stock market saw a significant upsurge in the AI pharmaceuticals sector,...

Company

LinkZill Completes Multi-Million-Dollar A-Round Financing Led by ProximaVentures

Fineline Cube Feb 14, 2025

Hangzhou LinkZill Technology Co., Ltd. has recently completed a multi-million-dollar A-round financing, exclusively led by...

Policy / Regulatory

New Guidelines for Advanced Gastric Cancer Drug Development Released in China

Fineline Cube Feb 14, 2025

The National Medical Products Administration (NMPA) of China has published the “Guidance Principles for Clinical...

Posts pagination

1 … 207 208 209 … 661

Recent updates

  • Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist
  • GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook
  • Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%
  • Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion
  • China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Company

GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook

Company

Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%

Company

Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.